As of November 6, 2026, 4 holders' latest Schedule 13D or 13G filings report owning 5% or more of Travere Therapeutics Inc. The largest reported stake is Janus Henderson Group Plc's, at 11.9%. 19 filings are on record since July 29, 2025 (Schedule 13G/A, November 14, 2025).
Sell to companies like Travere Therapeutics Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Fmr LLC · Sole voting: 4,978,970 · Shared voting: 0 · Sole dispositive: 5,707,883 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-11-05
- · Reporting person: Armistice Capital, LLC · Sole voting: 0 · Shared voting: 1,572,539 · Sole dispositive: 0 · Shared dispositive: 1,572,539 · SCHEDULE 13G/A, 2026-08-14
- · Reporting person: Bank Of America Corp · Sole voting: 0 · Shared voting: 5,103,492 · Sole dispositive: 0 · Shared dispositive: 5,325,237 · SCHEDULE 13G, 2026-08-12
- · Reporting person: State Street Corporation · Sole voting: 0 · Shared voting: 4,010,969 · Sole dispositive: 0 · Shared dispositive: 4,256,224 · SCHEDULE 13G, 2026-08-07
- · Holder: Fmr LLC · Percent: 7.7% · SCHEDULE 13G/A
Travere Therapeutics Inc has 19 Schedule 13D or 13G filings on record since 2025-07-29. 4 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Janus Henderson Group Plc | 11.9% | 10,599,660 | SCHEDULE 13G/A, 2025-11-14 | 2025-09-30 |
| Fmr LLC | 6.1% | 5,707,883 | SCHEDULE 13G/A, 2026-11-05 | 2026-09-30 |
| Bank Of America Corp | 5.8% | 5,439,155 | SCHEDULE 13G, 2026-08-12 | 2026-06-30 |
| Vanguard Capital Management | 5.09% | 4,699,424 | SCHEDULE 13G, 2026-04-30 | 2026-03-31 |
| Perceptive Advisors LLC | 4.8% | 4,278,180 | SCHEDULE 13G/A, 2026-02-17 | 2025-12-31 |
| State Street Corporation | 4.6% | 4,256,224 | SCHEDULE 13G, 2026-08-07 | 2026-06-30 |
| Armistice Capital, LLC | 1.67% | 1,572,539 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| The Vanguard Group | 0% | 0 | SCHEDULE 13G/A, 2026-03-27 | 2026-03-13 |
| Macquarie Group Limited | 0% | 0 | SCHEDULE 13G/A, 2026-02-13 | 2025-12-31 |
Holding shares or following this stake? See who's behind Travere Therapeutics Inc and the warning signs.
Free to see. No signup.
Keep reading
More on Travere Therapeutics Inc and the records around it.
Travere Therapeutics Inc elsewhere on the record
- Leadership changes Sep 2026
- Who owns it
Companies that share a holder
- Macquarie Group Limited also filed stake reports on 14 other companies: Artivion Inc (Feb 2026), Imax Corp (Feb 2026), Kaiser Aluminum Corp (Feb 2026)
- Perceptive Advisors LLC also filed stake reports on 57 other companies: Nautilus Biotechnology, Inc. (Nov 2026), Athira Pharma, Inc. (Oct 2026), IRulya Therapeutics Inc. (Oct 2026)
- BANK OF AMERICA CORP /DE/ also filed stake reports on 74 other companies: BlackRock 2037 Municipal Target Term Trust (Nov 2026), TRIMAS CORP (Nov 2026), PIMCO CALIFORNIA MUNICIPAL INCOME FUND (Nov 2026)
Watch Travere Therapeutics Inc
Get an email when Travere Therapeutics Inc files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Travere Therapeutics Inc?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Travere Therapeutics Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Travere Therapeutics Inc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
22 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Fmr LLC | 4,978,970 | 0 | 5,707,883 | 0 | SCHEDULE 13G/A, 2026-11-05 |
| Abigail P. Johnson | 0 | 0 | 5,707,883 | 0 | SCHEDULE 13G/A, 2026-11-05 |
| Bank Of America Corp | 0 | 5,103,492 | 0 | 5,325,237 | SCHEDULE 13G, 2026-08-12 |
| State Street Corporation | 0 | 4,010,969 | 0 | 4,256,224 | SCHEDULE 13G, 2026-08-07 |
| Armistice Capital, LLC | 0 | 1,572,539 | 0 | 1,572,539 | SCHEDULE 13G/A, 2026-08-14 |
| Steven Boyd | 0 | 1,572,539 | 0 | 1,572,539 | SCHEDULE 13G/A, 2026-08-14 |
The latest filing identifies Travere Therapeutics Inc by CUSIP 89422G107 and gives its principal executive office as 3611 VALLEY CENTRE DR, SUITE 300, SAN DIEGO, CA 92130 (SCHEDULE 13G/A, 2026-11-05).
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-29 | The Vanguard Group | 6.74% | SCHEDULE 13G/A |
| 2025-08-07 | Janus Henderson Group Plc | 12.8% | SCHEDULE 13G/A |
| 2025-08-15 | Armistice Capital, LLC | 9.96% | SCHEDULE 13G/A |
| 2025-10-14 | Perceptive Advisors LLC | 5.5% | SCHEDULE 13G |
| 2025-11-14 | Armistice Capital, LLC | 7.52% | SCHEDULE 13G/A |
| 2025-11-14 | Janus Henderson Group Plc | 11.9% | SCHEDULE 13G/A |
| 2026-01-08 | Fmr LLC | 11.7% | SCHEDULE 13G |
| 2026-02-09 | State Street Corporation | 5.3% | SCHEDULE 13G |
| 2026-02-13 | Macquarie Group Limited | 0% | SCHEDULE 13G/A |
| 2026-02-17 | Armistice Capital, LLC | 4.21% | SCHEDULE 13G/A |
| 2026-02-17 | Perceptive Advisors LLC | 4.8% | SCHEDULE 13G/A |
| 2026-03-27 | The Vanguard Group | 0% | SCHEDULE 13G/A |
| 2026-04-30 | Vanguard Capital Management | 5.09% | SCHEDULE 13G |
| 2026-05-15 | Armistice Capital, LLC | 5.27% | SCHEDULE 13G |
| 2026-08-06 | Fmr LLC | 7.7% | SCHEDULE 13G/A |
| 2026-08-07 | State Street Corporation | 4.6% | SCHEDULE 13G |
| 2026-08-12 | Bank Of America Corp | 5.8% | SCHEDULE 13G |
| 2026-08-14 | Armistice Capital, LLC | 1.67% | SCHEDULE 13G/A |
| 2026-11-05 | Fmr LLC | 6.1% | SCHEDULE 13G/A |
Questions about who owns Travere Therapeutics Inc
Who owns Travere Therapeutics Inc?
On this page, 4 holders' latest ownership filings report 5% or more of Travere Therapeutics Inc: Janus Henderson Group Plc (11.9%, Schedule 13G/A, filed 2025-11-14), Fmr LLC (6.1%, Schedule 13G/A, filed 2026-11-05), Bank Of America Corp (5.8%, Schedule 13G, filed 2026-08-12) and Vanguard Capital Management (5.09%, Schedule 13G, filed 2026-04-30).
Who are the largest shareholders of Travere Therapeutics Inc?
By the share each holder's latest filing reports, the largest holders of Travere Therapeutics Inc on this page are Janus Henderson Group Plc (11.9%), Fmr LLC (6.1%) and Bank Of America Corp (5.8%).
When did Janus Henderson Group Plc buy into Travere Therapeutics Inc?
The filings give report dates, not purchase dates. The earliest filing from Janus Henderson Group Plc on this page is the Schedule 13G/A, filed 2025-08-07, reporting 12.8%; its latest, Schedule 13G/A filed 2025-11-14, reports 11.9%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 19 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Travere Therapeutics Inc
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| September 21, 2026 | Leadership change: Bradley L. Campbell appointed, President and Chief Executive Officer | — | Leadership changes | Source |
| July 9, 2026 | Leadership change: Sandra Calvin departs | — | Leadership changes | Source |
| June 16, 2026 | Leadership change: William Rote departs, Chief Research Officer, and 1 more | — | Leadership changes | Source |
Tools for this story
Each opens in a new tab, filled in for Travere Therapeutics Inc. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.